| Title |
Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels?
|
|---|---|
| Published in |
Current Atherosclerosis Reports, November 2010
|
| DOI | 10.1007/s11883-010-0149-9 |
| Pubmed ID | |
| Authors |
Keith C. Ferdinand |
| Abstract |
Statins reduce coronary heart disease (CHD) morbidity and mortality over a wide range of patients. The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) in subjects with elevated C-reactive protein, without vascular disease and below average low-density lipoprotein cholesterol (LDL-C) showed a 50% reduction in LDL-C with 20 mg/d of rosuvastatin and a reduction in cardiovascular events (hazard ratio 0.56 [95% CI, 0.46-0.69]; P < 0.00001), and a reduction in total mortality (20%; P < 0.02). Recent commentary has criticized perceived JUPITER design flaws and inappropriate influence. However, the Canadian 2009 guidelines cite JUPITER as class I evidence for statin benefit. Although the Cholesterol Treatment Trialists' (CTT) Collaborators showed that, regardless of pre-treatment levels, statins can significantly reduce CHD, major vascular events, and overall mortality, a recent primary prevention meta-analysis showed no decrease in all-cause mortality. Preconceived notions on statin benefit or harm do not enhance patient care and clinicians should individualize long-term statin therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 4% |
| Canada | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 50 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 13% |
| Researcher | 7 | 13% |
| Student > Bachelor | 6 | 11% |
| Student > Postgraduate | 5 | 9% |
| Student > Master | 5 | 9% |
| Other | 13 | 24% |
| Unknown | 11 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 46% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 11% |
| Agricultural and Biological Sciences | 3 | 6% |
| Business, Management and Accounting | 1 | 2% |
| Nursing and Health Professions | 1 | 2% |
| Other | 4 | 7% |
| Unknown | 14 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2016.
All research outputs
#7,451,942
of 22,782,096 outputs
Outputs from Current Atherosclerosis Reports
#346
of 763 outputs
Outputs of similar age
#53,987
of 180,039 outputs
Outputs of similar age from Current Atherosclerosis Reports
#1
of 5 outputs
Altmetric has tracked 22,782,096 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 763 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 180,039 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them